Back to News
Market Impact: 0.2
Guggenheim Initiates Coverage of Entera Bio with Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Guggenheim initiated coverage of Entera Bio (NASDAQCM: ENTX) with a Buy rating on September 25, 2026. The positive initiation follows Cantor Fitzgerald beginning coverage with an Overweight recommendation on September 22, signaling favorable early analyst sentiment toward the biotech company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ENTX0.55
More News
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Why Microsoft Stock Is Up Today
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Beware borrowing costs: The jump in yields could hit these debt-laden stocks the most
- Details on U.S.-China trade negotiations coming Monday, USTR Greer says